Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gordon

Showing results (1101-1110 of 1,291) with videos related to

Pageof 130
Sort By:
Regional Anesthesia and Pain Medicine|July 20, 2006
Acute post-surgical pain management: a critical appraisal of current practice, December 2-4, 2005James P Rathmell, Christopher L Wu, Raymond S Sinatra, et al.
Chempluschem|November 30, 2023
Biomedical Applications of Electro-Initiated Polymerisation on Ti6Al4 V Titanium Alloy using Silk Fibroin Coatings for Antibiotic Delivery and Improved Cell MetabolismNicholas S Emonson, Bhagya Dharmasiri, Edward B Gordon, et al.
AIDS (London, England)|June 26, 2021
Incidence of HIV-positive admission and inpatient mortality in Malawi (2012-2019)Rachael M Burke, Marc Y R Henrion, Jane Mallewa, et al.
Genetics|April 22, 2016
Efficient Genome-Wide Sequencing and Low-Coverage Pedigree Analysis from Noninvasively Collected SamplesNoah Snyder-Mackler, William H Majoros, Michael L Yuan, et al.
Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Physical & Occupational Therapy in Pediatrics|January 11, 2023
Baseline Range of Motion, Strength, Motor Function, and Participation in Youth with Hutchinson-Gilford Progeria SyndromeJulie Malloy, Emily Berry, Annette Correia, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 20, 2011
Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndromeIngrid A Harten, Rima S Zahr, Joan M Lemire, et al.
Lancet (London, England)|August 3, 1996
An inhibitor of the sodium pump obtained from human placentaP J Hilton, R W White, G A Lord, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Pageof 130

Showing results (1101-1110 of 1,291) with videos related to

Sort By:
Pageof 130
Regional Anesthesia and Pain Medicine|July 20, 2006
Acute post-surgical pain management: a critical appraisal of current practice, December 2-4, 2005James P Rathmell, Christopher L Wu, Raymond S Sinatra, et al.
Chempluschem|November 30, 2023
Biomedical Applications of Electro-Initiated Polymerisation on Ti6Al4 V Titanium Alloy using Silk Fibroin Coatings for Antibiotic Delivery and Improved Cell MetabolismNicholas S Emonson, Bhagya Dharmasiri, Edward B Gordon, et al.
AIDS (London, England)|June 26, 2021
Incidence of HIV-positive admission and inpatient mortality in Malawi (2012-2019)Rachael M Burke, Marc Y R Henrion, Jane Mallewa, et al.
Genetics|April 22, 2016
Efficient Genome-Wide Sequencing and Low-Coverage Pedigree Analysis from Noninvasively Collected SamplesNoah Snyder-Mackler, William H Majoros, Michael L Yuan, et al.
Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Physical & Occupational Therapy in Pediatrics|January 11, 2023
Baseline Range of Motion, Strength, Motor Function, and Participation in Youth with Hutchinson-Gilford Progeria SyndromeJulie Malloy, Emily Berry, Annette Correia, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 20, 2011
Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndromeIngrid A Harten, Rima S Zahr, Joan M Lemire, et al.
Lancet (London, England)|August 3, 1996
An inhibitor of the sodium pump obtained from human placentaP J Hilton, R W White, G A Lord, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Pageof 130